Systematic review on quality of life measures in eczema trials



Similar documents
Quality of Life Measures in Atopic Dermatitis Clinical Care

Quality of Life and Illness Perception in Adult EB Clinic Patients

Patient Education in Chronic Skin Diseases: A Systematic Review

Instrument: Nail Assessment in Psoriasis and Psoriatic Arthritis

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Protocol registration and outcome reporting bias in randomised controlled trials of

Adalimumab for the treatment of psoriasis

Psoriasis, Incidence, Quality of Life, Psoriatic Arthritis, Prevalence

Impact of Psoriasis on Quality of Life at Hera General Hospital in Makkah, Saudi Arabia

Observational studies on homeopathy

Summary 1. Comparative-effectiveness

100% WHEY PROTEIN PARTIALLY HYDROLYZED in Infant Formula and REDUCING THE RISK OF ALLERGY IN INFANTS EXECUTIVE SUMMARY

Alexandra Bargiota Assist. Prof. in Endocrinology University Hopsital of Larissa Thessaly, Greece.

Breast cancer treatment for elderly women: a systematic review

How patients experience psoriasis: results from a European survey

The efficacy of a far erythemogenic dose of narrow- band UVB phototherapy in chronic plaque type psoriasis

Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author

Work-related diseases of occupational therapists - pilot study for creating an "occupational therapist-cohort" in Germany

New perception of disability including cognition, fatigue, pain and other impairments related to MS

completenutrition I R E L A N D The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr

Marketing Authorisation Holder (Invented) Name Strength Pharmaceutical Form

WAKE-Up Pilot Study, Mental Training for patients with relapse-remitting multiple sclerosis and fatigue

Springer-Verlag Berlin Heidelberg GmbH

Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Adults: A Six-Month Study

ustekinumab 45mg solution for injection in pre-filled syringe (Stelara ) SMC No. (944/14) Janssen-Cilag Ltd

Privatisation in German Health Care

How To Understand The Atop

Clinical Spotlight in Breast Cancer

SICKNESS ABSENCE POLICY

Secondary Use of the EHR via Pseudonymisation

Guidance document for the classification of dangerous goods with regard to their "corrosive effect on living tissue"

Master Programmes at the University of Basel

Presented By: Amy Medley PhD, MPH Centers for Disease Control and Prevention

Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015

The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process

Security Vendor Benchmark 2016 A Comparison of Security Vendors and Service Providers

Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement

Diagnosis communication and patients coping strategies. Dawn Langdon PhD

The Blood Donor BIOBANK

Dimethyl fumarate for treating relapsing remitting multiple sclerosis

Wider Implementation of Telemedicine in Estonia

ECZEMA: YOUR GP THE SECRETS WON T TELL YOU

ECRIN General Presentation

Marina Richardson, M.Sc. Deb Willems, BSc.PT David Ure, OT Robert Teasell, MD FRCPC

Accurate Assessment Instruments in Rehabilitation

FACULTY OF HEALTH AND MEDICAL SCIENCES UNIVERSITY OF COPENHAGEN. PhD thesis. Hand eczema. Self-management and prognosis 2014

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Overview: What are PROMs and PREMs? Raj Verma Director, Clinical Program Design & Implementation, ACI

The EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2012) Germany

Introduction Objective Methods Results Conclusion

Prospective multicenter study for functional evaluation of transoral laser microsurgery (TLM) for supraglottic carcinomas - SUPRATOL

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Federal Ministry of Education and Research

Gestione della dermatite atopica

Vitamin D und seine Bedeutung im Immunsystem und bei der Infektabwehr

påçííáëü=jéçáåáåéë=`çåëçêíáìã==

I. Background. II. Eligibility Geographic Scope: United States Only International(specify country/countries)

Dry eyes holding you back? Ask your doctor about LipiFlow.

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

SDM in occupation reintegration programs in medical rehabilitation

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

Transcription:

Christian Dr. Max Mustermann Apfelbacher Medizinische Referat Kommunikation Soziologie & Marketing Fakultät Verwaltung Medizin Systematic review on quality of life measures in eczema trials Current status and first results Daniel Heinl, Joanne Chalmers & Christian Apfelbacher Institut für Epidemiologie und Präventivmedizin

Background (1) Eczema is a common skin disease that affects both children and adults Eczema takes a chronic or chronically relapsing course, main symptom is pruritus Eczema exerts a negative impact on the quality of life (QoL) of patients and their families

Background (2) Due to unstandardized outcomes measures in eczema trials, evidence based decision making is difficult Therefore, the Harmonising Outcomes for Eczema (HOME) initiative defined a core set of outcome domains (COS) to be applied in all future eczema trials QoL is part of this COS A systematic review on QoL measures used in eczema trials is the first step of the HOME roadmap

Methods GREAT database screened for eligible eczema trials Eligibility criteria: 287 full texts and 72 - eczema trial abstracts included - published from 2000 onwards - indexed in GREAT Data database extraction: by no Various later than 31 May 2014 assessments, e.g. number - full text or abstract of outcomes, availabepros, in English quality or German of life Double data extraction for quality assurance 19 full texts and abstracts excluded RESULTS

Data extraction Full texts Number of outcomes, total Number of outcomes, reported Number of PROs Number of PROs, reported Number of composite indices Number of composite indices, reported Number of indices used Number of validated indices used Full texts (cont.) Assessment of safety Assessment of adverse events Primary endpoint Assessment of QoL QoL instruments used Abstracts Assessment of QoL QoL instruments used

Results full texts 287 papers reporting on 303 studies 35 Number of studies Number of studies 30 25 20 15 10 5 0 Year

Results full texts Outcome Result Number of outcomes, total 2,633 Percentage of PROs (including composite indices), total 30.73% (809) Percentage of composite indices, total 6.68% (176) Percentage of PROs (without composite indices), total 24.04% (633) Number of full text articles 287 Number of studies 303 Studies assessing quality of life 20.79% (63) Quality of life instruments used 22

Results quality of life (adults) Instrument Number of studies Full name (Reference) DLQI 20 (56%) Dermatology Life Quality Index (Finlay 1994) Skindex-29 2 (6%) (Chren 1997) Subtotal 22 (61%) TOTAL 36 (100%)

Results quality of life (adults) Instrument Number of studies Full name (Reference) EDLQ 1 (3%) Everyday Life Questionnaire/Alltagsleben (Bullinger 1993) EQ-5D 1 (3%) EuroQol-5D (Rabin 2001) SF-36 1 (3%) Short form 36 (McHorney 1993) SIP 1 (3%) Sickness Impact Profile (Gilson 1975) WTP 1 (3%) Willingness to pay (Schiffner 2003) DIELH 1 (3%) Deutsches Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen (Schäfer 2001) DLQI (modified) 1 (3%) Dermatology Life Quality Index (Finlay 1994) FLQA-d 1 (3%) Freiburg Life Quality Assessment d (Augustin 2000) ISDL (modified) 1 (3%) Impact of Chronic Skin Disease on Daily Life (Evers 2005) Self-provided 1 (3%) (Bissonette 2010) Skindex-16 1 (3%) (Chren 2001) Skindex-17 1 (3%) (Nijsten 2006) EDI 1 (3%) Eczema Disability Index (Salek 1993) QoLIAD 1 (3%) Quality of Life Index for Atopic Dermatitis (Whalley 2004) Subtotal 14 (39%) TOTAL 36 (100%)

Results quality of life (children, self-reported) Instrument Number of studies Full name (Reference) CDLQI 18 (90%) CDLQI (modified) 2 (10%) Children s Dermatology Life Quality Index (Lewis-Jones 1995) Children s Dermatology Life Quality Index (Lewis-Jones 1995) TOTAL 20 (100%)

Results quality of life (children, proxy-reported) Instrument Number of studies Full name (Reference) IDQOL 14 (93%) Infants Dermatology Quality of Life Index (Lewis- Jones 2001) Self-provided 1 (7%) (Wu 2012) TOTAL 15 (100%)

Results quality of life (carers) Instrument Number of studies Full name (Reference) DFI 14 (70%) Questionnaire by Rüden et al. PIQoL-AD 2 (10%) Dermatitis Family Impact (Lawson 1998) 3 (15%) (Rüden 1999) Parents Index of Quality of Life in Atopic Dermatitis (McKenna 2005) Self-provided 1 (5%) (Harper 2000) TOTAL 20 (100%)

Results quality of life over time (1) Left: Findings from Rehal 2011 Assessment of QoL Right: Our findings 30.00% 25.00% Percent QoL 20.00% 15.00% 10.00% 5.00% 0.00% 2000-2004 2005-2010 2011-2014 Years

Results quality of life over time (2) 60% 50% Assessment of QoL 35 30 40% 25 Percent QoL 30% 20% 20 15 10 10% 5 0% 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Percent QoL 25% 15% 19% 6% 21% 0% 31% 21% 27% 8% 28% 30% 32% 15% 50% N 12 20 21 16 14 22 26 24 22 25 25 33 19 20 4 0

Results - abstracts 72 abstracts included 4 abstract assessed quality of life (6%) Applied instruments: CDLQI (2x) DFI (1x) No closer specification (3x)

Discussion 1 out of 5 eczema trials assesses QoL Measurement of QoL has not increased substantially since 2000 Eczema-specific questionnaires are almost not used (adults, carers) or do not exist (children)

Thank you very much for your attention!